Product image of Wezenla (Ustekinumab) supplied by GNH India

Wezenla

Active Ingredient:
Ustekinumab
Origin:
EU

Wezenla (Ustekinumab)

Wezenla (ustekinumab) is a biologic therapy used for immune-mediated conditions. This EU-sourced intravenous formulation supports moderate to severe symptom management. Designed for targeted immune modulation, it is prescribed when conventional treatments are insufficient. Always consult a healthcare provider for suitability and monitoring.

Manufacturer / TM Owner

Amgen Technology (Ireland) Uc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Ustekinumab, the active ingredient in Wezenla, is prescribed for immune-related conditions such as moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It works by targeting specific proteins involved in inflammation. Patients often ask, 'what is ustekinumab used for' when considering treatment options for chronic inflammatory disorders.

Side Effects

  • Patients may notice reduced symptoms such as joint pain or skin plaques over time with ustekinumab therapy. The medication is designed to modulate immune responses, which can lead to gradual improvement in disease activity. Individual responses vary, and consistent use is often required for optimal benefit.

Precautions & Warnings

  • Store Wezenla as directed by healthcare professionals, typically refrigerated but protected from freezing. Keep out of reach of children and pets. Avoid exposure to extreme temperatures or direct sunlight. Always follow handling instructions provided with the medication to maintain stability and safety.

Avoid Interactions

  • Ustekinumab may interact with other biologics or immunosuppressants, potentially increasing infection risk. Live vaccines should be avoided during treatment unless approved by a doctor. Inform healthcare providers about all current medications to assess compatibility and minimize potential risks.

Frequently Asked Questions

Wezenla (ustekinumab) is used to treat immune-mediated conditions like plaque psoriasis, psoriatic arthritis, and Crohn’s disease.

Wezenla is given as an intravenous infusion by a healthcare professional, typically in a clinical setting.

Consult your healthcare provider before using Wezenla if pregnant or planning pregnancy to assess potential risks and benefits.

Common effects may include headache, tiredness, or injection site reactions; report persistent issues to your doctor.

Yes, Wezenla contains ustekinumab, a biologic therapy designed to target specific immune pathways.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ustekinumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT